How to buy Acceleron Pharma (XLRN) stock

Acceleron Pharma Inc is a biotechnology business based in the US. Acceleron Pharma shares (XLRN) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 312 staff and has a trailing 12-month revenue of around 0.00.

Acceleron Pharma stock price (NASDAQ: XLRN)

Use our graph to track the performance of XLRN stocks over time.

Acceleron Pharma shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$131.81
52-week range	$85.58 - $146.15
50-day moving average	$124.08
200-day moving average	$126.86
Wall St. target price	$155.69
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.44

Buy Acceleron Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Acceleron Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Acceleron Pharma Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acceleron Pharma price performance over time

Historical closes compared with the close of $131.81 from 2021-05-26

1 week (2021-07-14)	N/A
1 month (2021-06-25)	3.61%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

Acceleron Pharma financials

Revenue TTM	$112.9 million
Gross profit TTM	$-81,394,000
Return on assets TTM	-16.73%
Return on equity TTM	-29.16%
Profit margin	-158.11%
Book value	$13.37
Market capitalisation	$7.5 billion

TTM: trailing 12 months

Shorting Acceleron Pharma shares

There are currently 2.1 million Acceleron Pharma shares held short by investors – that's known as Acceleron Pharma's "short interest". This figure is 9.4% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Acceleron Pharma shares can be evaluated.

Acceleron Pharma's "short interest ratio" (SIR)

Acceleron Pharma's "short interest ratio" (SIR) is the quantity of Acceleron Pharma shares currently shorted divided by the average quantity of Acceleron Pharma shares traded daily (recently around 286810.0536193). Acceleron Pharma's SIR currently stands at 7.46. In other words for every 100,000 Acceleron Pharma shares traded daily on the market, roughly 7460 shares are currently held short.

However Acceleron Pharma's short interest can also be evaluated against the total number of Acceleron Pharma shares, or, against the total number of tradable Acceleron Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acceleron Pharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Acceleron Pharma shares in existence, roughly 40 shares are currently held short) or 0.04% of the tradable shares (for every 100,000 tradable Acceleron Pharma shares, roughly 40 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Acceleron Pharma.

Find out more about how you can short Acceleron Pharma stock.

Acceleron Pharma share dividends

We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.

Acceleron Pharma share price volatility

Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $85.58 up to $146.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.3547. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).

Acceleron Pharma overview

Acceleron Pharma Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc.

Frequently asked questions

What percentage of Acceleron Pharma is owned by insiders or institutions?
Currently 11.865% of Acceleron Pharma shares are held by insiders and 90.562% by institutions. How many people work for Acceleron Pharma?
Latest data suggests 312 work at Acceleron Pharma. When does the fiscal year end for Acceleron Pharma?
Acceleron Pharma's fiscal year ends in December. Where is Acceleron Pharma based?
Acceleron Pharma's address is: 128 Sidney Street, Cambridge, MA, United States, 02139 What is Acceleron Pharma's ISIN number?
Acceleron Pharma's international securities identification number is: US00434H1086 What is Acceleron Pharma's CUSIP number?
Acceleron Pharma's Committee on Uniform Securities Identification Procedures number is: 00434H108